Healthcare distributor and services company Cardinal Health (NYSE: CAH) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 5.8% year on year to $63.67 billion. Its non-GAAP profit of $2.91 per share was 20.2% above analysts’ consensus estimates.
Is now the time to buy Cardinal Health? Find out by accessing our full research report, it’s free.
Cardinal Health (CAH) Q2 CY2026 Highlights:
- Revenue: $63.67 billion vs analyst estimates of $65.42 billion (5.8% year-on-year growth, 2.7% miss)
- Adjusted EPS: $2.91 vs analyst estimates of $2.42 (20.2% beat)
- Adjusted EPS guidance for the upcoming financial year 2027 is $12.50 at the midpoint, beating analyst estimates by 3.7%
- Operating Margin: 1.1%, in line with the same quarter last year
- Free Cash Flow Margin: 2.2%, similar to the same quarter last year
- Market Capitalization: $55.55 billion
"Fiscal 2026 was a standout year for Cardinal Health and I am pleased with our strong fourth quarter results," said Jason Hollar, CEO of Cardinal Health.
Company Overview
Operating as a critical link in the healthcare supply chain since 1979, Cardinal Health (NYSE: CAH) distributes pharmaceuticals and manufactures medical products for hospitals, pharmacies, and healthcare providers across the global healthcare supply chain.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Cardinal Health’s sales grew at a decent 9.4% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Cardinal Health’s recent performance shows its demand has slowed as its annualized revenue growth of 5.9% over the last two years was below its five-year trend. We’re wary when companies in the sector see decelerations in revenue growth, as it could signal changing consumer tastes aided by low switching costs. 
This quarter, Cardinal Health’s revenue grew by 5.8% year on year to $63.67 billion, missing Wall Street’s estimates.
Looking ahead, sell-side analysts expect revenue to grow 8.8% over the next 12 months, an improvement versus the last two years. This projection is particularly noteworthy for a company of its scale and indicates its newer products and services will spur better top-line performance.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Cardinal Health’s adjusted operating margin has generally stayed the same over the last 12 months, averaging 1.2% over the last five years. This profitability was lousy for a healthcare business and caused by its suboptimal cost structure.
Looking at the trend in its profitability, Cardinal Health’s adjusted operating margin might have fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.
In Q2, Cardinal Health generated an adjusted operating margin profit margin of 1.2%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Cardinal Health’s EPS grew at 15.2% compounded annual growth rate over the last five years, higher than its 9.4% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its adjusted operating margin didn’t improve.
Diving into the nuances of Cardinal Health’s earnings can give us a better understanding of its performance. A five-year view shows that Cardinal Health has repurchased its stock, shrinking its share count by 19.8%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings. 
In Q2, Cardinal Health reported adjusted EPS of $2.91, up from $2.08 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Cardinal Health’s full-year EPS to grow 7.1% from $11.26 to $12.05.
Key Takeaways from Cardinal Health’s Q2 Results
It was good to see Cardinal Health beat analysts’ EPS expectations this quarter. We were also glad its full-year EPS guidance outperformed Wall Street’s estimates. On the other hand, its revenue missed. Overall, this print had some key positives. The stock traded up 3.5% to $246.85 immediately after reporting.
So should you invest in Cardinal Health right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).
